Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg (CAMON)
This study has been completed.
Information provided by (Responsible Party):
First received: June 11, 2009
Last updated: January 21, 2013
Last verified: January 2013
To gather information on the safety of monotherapy of Casodex® tablets 80 mg, targeting prostate cancer patients who have no history of having received treatment by either endocrine therapy (including surgical castration).
||Observational Model: Cohort
Time Perspective: Prospective
||Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Primary Outcome Measures:
- Adverse event incidence [ Time Frame: Time since starting Casodex monotherapy, monthly ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- improvement of prostate cancer using Tumor marker PSA [ Time Frame: Time since starting Casodex monotherapy, monthly ] [ Designated as safety issue: No ]
- Maintenance of sexual function [ Time Frame: At 3 months since starting Casodex monotherapy, ] [ Designated as safety issue: Yes ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||March 2012 (Final data collection date for primary outcome measure)
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Prostate cancer patients who have no history of having received treatment by either endocrine therapy (including surgical castration)
- Prostate cancer patients who have no history of receiving endocrine therapy (including surgical castration), and who plan to undergo Casodex® tablets monotherapy for not less than 12 months
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00919477
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 11, 2009
||January 21, 2013
||Japan: Institutional Review Board
Keywords provided by AstraZeneca:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 26, 2015
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site